Advanced in Olfactory Neuroblastoma

Dr. Voichita Bar Ad

Radiation Oncology
Jefferson University Physicians
111 S 11th St, 1st Flr Bodine Ctr, 
Philadelphia, PA 
Offers Telehealth
Advanced in Olfactory Neuroblastoma
Jefferson University Physicians
111 S 11th St, 1st Flr Bodine Ctr, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Voichita Bar Ad is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Bar Ad is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, Atypical Teratoid Rhabdoid Tumor (ATRT), Neuroepithelioma, and Gamma Knife Radiosurgery.

Her clinical research consists of co-authoring 11 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in PA
Hospital Affiliations
Jefferson Stratford Hospital
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

JEFFERSON UNIVERSITY PHYSICIANS
111 S 11th St, 1st Flr Bodine Ctr, Philadelphia, PA 19107

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer
A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer
Enrollment Status: Completed
Publish Date: September 19, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Early Phase 1
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Radiation, Other, Procedure
Study Phase: Phase 1
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling
Enrollment Status: Completed
Publish Date: May 20, 2025
Intervention Type: Dietary supplement
Study Phase: Not Applicable
TELEPORT STUDY: A Pilot Feasibility Trial Examining The Use of Telehealth in Post Radiation Therapy Visits
TELEPORT STUDY: A Pilot Feasibility Trial Examining The Use of Telehealth in Post Radiation Therapy Visits
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other
Study Phase: Not Applicable
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 1
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
View 7 Less Clinical Trials

11 Total Publications

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
Journal: Journal for immunotherapy of cancer
Published: July 16, 2023
Similar Doctors
Distinguished in Olfactory Neuroblastoma
Dr. Alexander Lin
Radiation Oncology
Distinguished in Olfactory Neuroblastoma
Dr. Alexander Lin
Radiation Oncology

Penn Radiation Oncology Perelman-Concourse Level

3400 Civic Center Boulevard, Concourse Level, 
Philadelphia, PA 
 (1.8 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexander Lin is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Lin is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Nasopharyngeal Carcinoma, Oral Squamous Cell Carcinoma, Teratocarcinosarcoma, and Olfactory Neuroblastoma. Dr. Lin is currently accepting new patients.

Distinguished in Olfactory Neuroblastoma
Dr. Michelle Alonso
Radiation Oncology
Distinguished in Olfactory Neuroblastoma
Dr. Michelle Alonso
Radiation Oncology

Penn Radiation Oncology Perelman - 2nd Floor

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (1.8 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michelle Alonso is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Alonso is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Chordoma, Brain Tumor, Posterior Fossa Tumor, Meningioma, and Gamma Knife Radiosurgery. Dr. Alonso is currently accepting new patients.

Distinguished in Olfactory Neuroblastoma
Dr. Michelle Gentile
Radiation Oncology
Distinguished in Olfactory Neuroblastoma
Dr. Michelle Gentile
Radiation Oncology

Penn Radiation Oncology Pennsylvania Hospital

800 Spruce Street, Widener Ground Level, 
Philadelphia, PA 
 (0.3 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michelle Gentile is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Gentile is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Adenoid Cystic Carcinoma, Teratocarcinosarcoma, Olfactory Neuroblastoma, and Angiosarcoma. Dr. Gentile is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bar Ad's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile